Comparison of the cardioprotective effects of liraglutide, dapagliflozin and their combination in a rat model of diabetes induced by streptozotocin.

Mayyas F, Omeish A

Life sciences17 May 2025Cited by 3 (Europe PMC)

PMID40389022DOI10.1016/j.lfs.2025.123721PepBankPUB-40389022

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study14

9 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In male Wistar rats with STZ-induced diabetes, liraglutide monotherapy lowered glucose; the exact comparison reference and analyzed N were unstated.
In plain wordsIn male Wistar rats with diabetes, liraglutide lowered glucose; the comparison reference was unspecified.
Peptide
Liraglutide
Outcome
DecreaseGlucose levels
Study
ratn: not reported in source
streptozotocin-induced diabetes
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.4 mg/kg · subcutaneous · 8 weeksAs given in this study (rat).
Source sentences
Summary
Dapagliflozin and/or liraglutide treatment lowered glucose levels, mostly in the combination group.
2 context sentences(design, population, supporting numbers)
Summary · context
Adult male Wistar rats were assigned into five groups (15-17 rats/group): control rats, diabetic rats (DM, single 50 mg/kg STZ intraperitoneally (IP)), diabetic rats treated with dapagliflozin (Dapa, 1 mg/kg by oral gavage), diabetic rats treated with liraglutide (Lira), 0.4 mg/kg subcutaneously (SC…
Summary · context
Cardiac biomarkers of inflammation, oxidative stress, and fibrosis were evaluated.
Report a problemFND-4038902201
02AnimalAnimal study (in vivo)Efficacy outcome
In male Wistar rats with STZ-induced diabetes, liraglutide monotherapy normalized the diabetes-elevated heart/body-weight ratio; the exact reference and analyzed N were unstated.
In plain wordsIn male Wistar rats with diabetes, liraglutide normalized the elevated heart/body-weight ratio; the comparison reference was unspecified.
Peptide
Liraglutide
Outcome
DecreaseHeart-to-body weight ratio
Study
ratn: not reported in source
streptozotocin-induced diabetes
Outcome group
Heart function · Cardiovascular
Studied dose
0.4 mg/kg · subcutaneous · 8 weeksAs given in this study (rat).
Source sentences
Summary
Diabetes increased heart/body weight ratio, which was normalized by all treatments.
2 context sentences(design, population, supporting numbers)
Summary · context
Adult male Wistar rats were assigned into five groups (15-17 rats/group): control rats, diabetic rats (DM, single 50 mg/kg STZ intraperitoneally (IP)), diabetic rats treated with dapagliflozin (Dapa, 1 mg/kg by oral gavage), diabetic rats treated with liraglutide (Lira), 0.4 mg/kg subcutaneously (SC…
Summary · context
Cardiac biomarkers of inflammation, oxidative stress, and fibrosis were evaluated.
Report a problemFND-4038902202
03AnimalAnimal study (in vivo)Efficacy outcome
In male Wistar rats with STZ-induced diabetes, adding liraglutide to dapagliflozin provided an added PAI-2 benefit versus dapagliflozin alone; its signed coefficient and analyzed N were unstated.
In plain wordsIn male Wistar rats with diabetes, adding liraglutide to dapagliflozin improved PAI-2 versus dapagliflozin alone; the signed effect was unstated.
Peptide
Liraglutide
Outcome
Direction not reportedPAI-2 level
Study
ratn: not reported in source
streptozotocin-induced diabetes
Comparator
dapagliflozin
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
0.4 mg/kg · subcutaneous · 8 weeksAs given in this study (rat).
Source sentences
Summary
Dapagliflozin normalized inflammatory markers levels, but combination with Lira added no benefit, except for PAI-2.
2 context sentences(design, population, supporting numbers)
Summary · context
Adult male Wistar rats were assigned into five groups (15-17 rats/group): control rats, diabetic rats (DM, single 50 mg/kg STZ intraperitoneally (IP)), diabetic rats treated with dapagliflozin (Dapa, 1 mg/kg by oral gavage), diabetic rats treated with liraglutide (Lira), 0.4 mg/kg subcutaneously (SC…
Summary · context
Cardiac biomarkers of inflammation, oxidative stress, and fibrosis were evaluated.
Report a problemFND-4038902205
04AnimalAnimal study (in vivo)Efficacy outcome
In male Wistar rats with STZ-induced diabetes, adding liraglutide to dapagliflozin further lowered cardiac total nitrite versus dapagliflozin alone; the coefficient and analyzed N were unstated.
In plain wordsIn male Wistar rats with diabetes, adding liraglutide further lowered total nitrite compared with dapagliflozin alone.
Peptide
Liraglutide
Outcome
DecreaseTotal nitrite level
Study
ratn: not reported in source
streptozotocin-induced diabetes
Comparator
dapagliflozin
Outcome group
Oxidative stress · Cardiovascular
Studied dose
0.4 mg/kg · subcutaneous · 8 weeksAs given in this study (rat).
Source sentences
Summary
Dapagliflozin normalized total nitrite and TBARS levels. Combining treatments further decreased nitrite and TBARS levels and normalized cardiac SOD activity.
2 context sentences(design, population, supporting numbers)
Summary · context
Adult male Wistar rats were assigned into five groups (15-17 rats/group): control rats, diabetic rats (DM, single 50 mg/kg STZ intraperitoneally (IP)), diabetic rats treated with dapagliflozin (Dapa, 1 mg/kg by oral gavage), diabetic rats treated with liraglutide (Lira), 0.4 mg/kg subcutaneously (SC…
Summary · context
Cardiac biomarkers of inflammation, oxidative stress, and fibrosis were evaluated.
Report a problemFND-4038902206
05AnimalAnimal study (in vivo)Efficacy outcome
In male Wistar rats with STZ-induced diabetes, adding liraglutide to dapagliflozin further lowered cardiac TBARS versus dapagliflozin alone; the coefficient and analyzed N were unstated.
In plain wordsIn male Wistar rats with diabetes, adding liraglutide further lowered TBARS compared with dapagliflozin alone.
Peptide
Liraglutide
Outcome
DecreaseTBARS level
Study
ratn: not reported in source
streptozotocin-induced diabetes
Comparator
dapagliflozin
Outcome group
Oxidative stress · Cardiovascular
Studied dose
0.4 mg/kg · subcutaneous · 8 weeksAs given in this study (rat).
Source sentences
Summary
Dapagliflozin normalized total nitrite and TBARS levels. Combining treatments further decreased nitrite and TBARS levels and normalized cardiac SOD activity.
2 context sentences(design, population, supporting numbers)
Summary · context
Adult male Wistar rats were assigned into five groups (15-17 rats/group): control rats, diabetic rats (DM, single 50 mg/kg STZ intraperitoneally (IP)), diabetic rats treated with dapagliflozin (Dapa, 1 mg/kg by oral gavage), diabetic rats treated with liraglutide (Lira), 0.4 mg/kg subcutaneously (SC…
Summary · context
Cardiac biomarkers of inflammation, oxidative stress, and fibrosis were evaluated.
Report a problemFND-4038902207
06AnimalAnimal study (in vivo)Efficacy outcome
In male Wistar rats with STZ-induced diabetes, adding liraglutide to dapagliflozin added no benefit for cardiac TNF-alpha versus dapagliflozin alone; the signed coefficient and test were unstated.
In plain wordsIn male Wistar rats with diabetes, adding liraglutide to dapagliflozin added no TNF-alpha benefit versus dapagliflozin alone; the test was unstated.
Peptide
Liraglutide
Outcome
Direction not reportedTumor necrosis factor-alpha level
Study
ratn: not reported in source
streptozotocin-induced diabetes
Comparator
dapagliflozin
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
0.4 mg/kg · subcutaneous · 8 weeksAs given in this study (rat).
Source sentences
Summary
Dapagliflozin normalized inflammatory markers levels, but combination with Lira added no benefit, except for PAI-2.
3 context sentences(design, population, supporting numbers)
Summary · context
DM increased cardiac inflammatory and oxidant markers, including tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), endothelin-1 (ET-1), myeloperoxidase (1), plasminogen activator inhibitor-2 (PAI-2), total nitrite, and thiobarbituric acid reactive substances (TBARS).
Summary · context
Adult male Wistar rats were assigned into five groups (15-17 rats/group): control rats, diabetic rats (DM, single 50 mg/kg STZ intraperitoneally (IP)), diabetic rats treated with dapagliflozin (Dapa, 1 mg/kg by oral gavage), diabetic rats treated with liraglutide (Lira), 0.4 mg/kg subcutaneously (SC…
Summary · context
Cardiac biomarkers of inflammation, oxidative stress, and fibrosis were evaluated.
Report a problemFND-4038902211
07AnimalAnimal study (in vivo)Efficacy outcome
In male Wistar rats with STZ-induced diabetes, adding liraglutide to dapagliflozin added no benefit for cardiac interleukin-6 versus dapagliflozin alone; the signed coefficient and test were unstated.
In plain wordsIn male Wistar rats with diabetes, adding liraglutide to dapagliflozin added no interleukin-6 benefit versus dapagliflozin alone; the test was unstated.
Peptide
Liraglutide
Outcome
Direction not reportedInterleukin-6 level
Study
ratn: not reported in source
streptozotocin-induced diabetes
Comparator
dapagliflozin
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
0.4 mg/kg · subcutaneous · 8 weeksAs given in this study (rat).
Source sentences
Summary
Dapagliflozin normalized inflammatory markers levels, but combination with Lira added no benefit, except for PAI-2.
3 context sentences(design, population, supporting numbers)
Summary · context
DM increased cardiac inflammatory and oxidant markers, including tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), endothelin-1 (ET-1), myeloperoxidase (1), plasminogen activator inhibitor-2 (PAI-2), total nitrite, and thiobarbituric acid reactive substances (TBARS).
Summary · context
Adult male Wistar rats were assigned into five groups (15-17 rats/group): control rats, diabetic rats (DM, single 50 mg/kg STZ intraperitoneally (IP)), diabetic rats treated with dapagliflozin (Dapa, 1 mg/kg by oral gavage), diabetic rats treated with liraglutide (Lira), 0.4 mg/kg subcutaneously (SC…
Summary · context
Cardiac biomarkers of inflammation, oxidative stress, and fibrosis were evaluated.
Report a problemFND-4038902212
08AnimalAnimal study (in vivo)Efficacy outcome
In male Wistar rats with STZ-induced diabetes, adding liraglutide to dapagliflozin added no benefit for cardiac endothelin-1 versus dapagliflozin alone; the signed coefficient and test were unstated.
In plain wordsIn male Wistar rats with diabetes, adding liraglutide to dapagliflozin added no endothelin-1 benefit versus dapagliflozin alone; the test was unstated.
Peptide
Liraglutide
Outcome
Direction not reportedEndothelin-1 level
Study
ratn: not reported in source
streptozotocin-induced diabetes
Comparator
dapagliflozin
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
0.4 mg/kg · subcutaneous · 8 weeksAs given in this study (rat).
Source sentences
Summary
Dapagliflozin normalized inflammatory markers levels, but combination with Lira added no benefit, except for PAI-2.
3 context sentences(design, population, supporting numbers)
Summary · context
DM increased cardiac inflammatory and oxidant markers, including tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), endothelin-1 (ET-1), myeloperoxidase (1), plasminogen activator inhibitor-2 (PAI-2), total nitrite, and thiobarbituric acid reactive substances (TBARS).
Summary · context
Adult male Wistar rats were assigned into five groups (15-17 rats/group): control rats, diabetic rats (DM, single 50 mg/kg STZ intraperitoneally (IP)), diabetic rats treated with dapagliflozin (Dapa, 1 mg/kg by oral gavage), diabetic rats treated with liraglutide (Lira), 0.4 mg/kg subcutaneously (SC…
Summary · context
Cardiac biomarkers of inflammation, oxidative stress, and fibrosis were evaluated.
Report a problemFND-4038902213
09AnimalAnimal study (in vivo)Efficacy outcome
In male Wistar rats with STZ-induced diabetes, adding liraglutide to dapagliflozin added no benefit for cardiac myeloperoxidase versus dapagliflozin alone; the signed coefficient and test were unstated.
In plain wordsIn male Wistar rats with diabetes, adding liraglutide to dapagliflozin added no myeloperoxidase benefit versus dapagliflozin alone; the test was unstated.
Peptide
Liraglutide
Outcome
Direction not reportedMyeloperoxidase level
Study
ratn: not reported in source
streptozotocin-induced diabetes
Comparator
dapagliflozin
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
0.4 mg/kg · subcutaneous · 8 weeksAs given in this study (rat).
Source sentences
Summary
Dapagliflozin normalized inflammatory markers levels, but combination with Lira added no benefit, except for PAI-2.
3 context sentences(design, population, supporting numbers)
Summary · context
DM increased cardiac inflammatory and oxidant markers, including tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), endothelin-1 (ET-1), myeloperoxidase (1), plasminogen activator inhibitor-2 (PAI-2), total nitrite, and thiobarbituric acid reactive substances (TBARS).
Summary · context
Adult male Wistar rats were assigned into five groups (15-17 rats/group): control rats, diabetic rats (DM, single 50 mg/kg STZ intraperitoneally (IP)), diabetic rats treated with dapagliflozin (Dapa, 1 mg/kg by oral gavage), diabetic rats treated with liraglutide (Lira), 0.4 mg/kg subcutaneously (SC…
Summary · context
Cardiac biomarkers of inflammation, oxidative stress, and fibrosis were evaluated.
Report a problemFND-4038902214

Studies that did not test the peptide alone5

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

10AnimalNot a test of Liraglutide aloneAnimal study (in vivo)Efficacy outcome
In male Wistar rats with STZ-induced diabetes, dapagliflozin/liraglutide treatment lowered glucose, with lowering reported mostly in the combined-treatment group; exact reference and individual comparison coefficients were unstated.
In plain wordsIn male Wistar rats with diabetes, dapagliflozin/liraglutide treatment lowered glucose; the exact comparison was unspecified.
Peptide
Liraglutide
Outcome
DecreaseGlucose levels
Study
ratn: not reported in source
streptozotocin-induced diabetes
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
Dapagliflozin and/or liraglutide treatment lowered glucose levels, mostly in the combination group.
2 context sentences(design, population, supporting numbers)
Summary · context
Adult male Wistar rats were assigned into five groups (15-17 rats/group): control rats, diabetic rats (DM, single 50 mg/kg STZ intraperitoneally (IP)), diabetic rats treated with dapagliflozin (Dapa, 1 mg/kg by oral gavage), diabetic rats treated with liraglutide (Lira), 0.4 mg/kg subcutaneously (SC…
Summary · context
Cardiac biomarkers of inflammation, oxidative stress, and fibrosis were evaluated.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4038902203
11AnimalNot a test of Liraglutide aloneAnimal study (in vivo)Efficacy outcome
In male Wistar rats with STZ-induced diabetes, dapagliflozin/liraglutide treatment normalized the diabetes-elevated heart/body-weight ratio; exact reference and native-drug contribution were unstated.
In plain wordsIn male Wistar rats with diabetes, dapagliflozin/liraglutide normalized the elevated heart/body-weight ratio; the exact comparison was unspecified.
Peptide
Liraglutide
Outcome
DecreaseHeart-to-body weight ratio
Study
ratn: not reported in source
streptozotocin-induced diabetes
Outcome group
Heart function · Cardiovascular
Source sentences
Summary
Diabetes increased heart/body weight ratio, which was normalized by all treatments.
2 context sentences(design, population, supporting numbers)
Summary · context
Adult male Wistar rats were assigned into five groups (15-17 rats/group): control rats, diabetic rats (DM, single 50 mg/kg STZ intraperitoneally (IP)), diabetic rats treated with dapagliflozin (Dapa, 1 mg/kg by oral gavage), diabetic rats treated with liraglutide (Lira), 0.4 mg/kg subcutaneously (SC…
Summary · context
Cardiac biomarkers of inflammation, oxidative stress, and fibrosis were evaluated.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4038902204
12AnimalNot a test of Liraglutide aloneAnimal study (in vivo)Efficacy outcome
In male Wistar rats with STZ-induced diabetes, combined dapagliflozin/liraglutide normalized cardiac SOD activity; the signed coefficient, exact reference and native-drug contribution were unstated.
In plain wordsIn male Wistar rats with diabetes, dapagliflozin/liraglutide normalized cardiac SOD activity; the signed effect and comparison were unspecified.
Peptide
Liraglutide
Outcome
Direction not reportedCardiac SOD activity
Study
ratn: not reported in source
streptozotocin-induced diabetes
Outcome group
Inflammation markers · Cardiovascular
Source sentences
Summary
Combining treatments further decreased nitrite and TBARS levels and normalized cardiac SOD activity.
2 context sentences(design, population, supporting numbers)
Summary · context
Adult male Wistar rats were assigned into five groups (15-17 rats/group): control rats, diabetic rats (DM, single 50 mg/kg STZ intraperitoneally (IP)), diabetic rats treated with dapagliflozin (Dapa, 1 mg/kg by oral gavage), diabetic rats treated with liraglutide (Lira), 0.4 mg/kg subcutaneously (SC…
Summary · context
Cardiac biomarkers of inflammation, oxidative stress, and fibrosis were evaluated.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4038902208
13AnimalNot a test of Liraglutide aloneAnimal study (in vivo)Efficacy outcome
In male Wistar rats with STZ-induced diabetes, combined dapagliflozin/liraglutide normalized cardiac fibrosis; the signed coefficient, exact reference and native-drug contribution were unstated.
In plain wordsIn male Wistar rats with diabetes, dapagliflozin/liraglutide normalized cardiac fibrosis; the signed effect and comparison were unspecified.
Peptide
Liraglutide
Outcome
Direction not reportedCardiac fibrosis
Study
ratn: not reported in source
streptozotocin-induced diabetes
Outcome group
Heart function · Cardiovascular
Source sentences
Summary
Both dapagliflozin and the combination normalized cardiac fibrosis and platelet-derived growth factor-BB (PDGF-BB) levels.
2 context sentences(design, population, supporting numbers)
Summary · context
Adult male Wistar rats were assigned into five groups (15-17 rats/group): control rats, diabetic rats (DM, single 50 mg/kg STZ intraperitoneally (IP)), diabetic rats treated with dapagliflozin (Dapa, 1 mg/kg by oral gavage), diabetic rats treated with liraglutide (Lira), 0.4 mg/kg subcutaneously (SC…
Summary · context
Cardiac biomarkers of inflammation, oxidative stress, and fibrosis were evaluated.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4038902209
14AnimalNot a test of Liraglutide aloneAnimal study (in vivo)Efficacy outcome
In male Wistar rats with STZ-induced diabetes, combined dapagliflozin/liraglutide normalized cardiac PDGF-BB; the signed coefficient, exact reference and native-drug contribution were unstated.
In plain wordsIn male Wistar rats with diabetes, dapagliflozin/liraglutide normalized cardiac PDGF-BB; the signed effect and comparison were unspecified.
Peptide
Liraglutide
Outcome
Direction not reportedPDGF-BB level
Study
ratn: not reported in source
streptozotocin-induced diabetes
Outcome group
Heart function · Cardiovascular
Source sentences
Summary
Both dapagliflozin and the combination normalized cardiac fibrosis and platelet-derived growth factor-BB (PDGF-BB) levels.
2 context sentences(design, population, supporting numbers)
Summary · context
Adult male Wistar rats were assigned into five groups (15-17 rats/group): control rats, diabetic rats (DM, single 50 mg/kg STZ intraperitoneally (IP)), diabetic rats treated with dapagliflozin (Dapa, 1 mg/kg by oral gavage), diabetic rats treated with liraglutide (Lira), 0.4 mg/kg subcutaneously (SC…
Summary · context
Cardiac biomarkers of inflammation, oxidative stress, and fibrosis were evaluated.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4038902210

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:04 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.

Comparison of the cardioprotective effects of liraglutide, dapagliflozin and their combination in a rat model of diabetes induced by streptozotocin.

Summary

Results from this study14

Studies that did not test the peptide alone5

Version history

Subjects

Publication types

MeSH terms

Keywords